Introduction
Pancreatic ductal adenocarcinoma (PDAC) carries a 5-year overall survival rate of approximately 12%, a figure that has improved only marginally over decades 6. Real-world evidence from 2022–2026 reveals that a mere 6% of US patients receive completely guideline-concordant comprehensive care 1. The disease's poor prognosis is attributable not solely to biologic aggressiveness, but to a cascade of remediable system-level failures: delayed diagnosis, inadequate molecular testing, fragmented multidisciplinary coordination, suboptimal adjuvant completion, and profound disparities in access. This review maps these gaps, links them to outcome data, and proposes actionable levers for improvement.
Diagnostic Delays and Staging Pathways
Late-stage presentation is the dominant driver of poor outcomes. Most PDAC cases are diagnosed at advanced stages that preclude curative resection 6. A French population-based study of 324 patients quantified the prognostic cost of delays: a time interval of 25 days or more between an initial medical visit and diagnostic imaging was independently associated with a 70% increase in 1-year mortality risk (HR 1.7, 95% CI 1.2–2.3) 2. Median intervals from visit to imaging were 15 days overall, but 27 days for patients ultimately diagnosed with unresectable disease versus 13 days for those with resectable disease 2. Importantly, consultation with a general practitioner prior to imaging contributed to longer delays (24 days) compared with direct specialist consultation (15 days) 2.
Barriers to early detection include the low incidence of PDAC in the general population, which makes universal screening impractical; the need to better define risk stratification and optimize surveillance implementation in high-risk groups; and limited validated biomarkers for population-level early detection. Serum biomarker and ctDNA-based approaches remain investigational 6. Serum biomarkers and ctDNA-based early detection approaches remain investigational, constrained by limited prospective multicenter validation and molecular heterogeneity 78.
| Time Interval | Median (Days) | Impact |
|---|---|---|
| Medical visit to diagnostic imaging | 15 [IQR 8–44] | Delay ≥25 days: HR 1.7 for 1-year mortality 2 |
| Diagnostic imaging to definitive diagnosis | 11 | Longer in unresectable disease 2 |
| Diagnostic imaging to first treatment | 20 | 22 days unresectable vs. 14 days resectable 2 |
Molecular and Germline Testing Gaps
Despite universal germline testing being a guideline-level recommendation for all PDAC patients 21, real-world adherence is strikingly deficient. An AccessHope analysis of 94 cases (2019–2022) found that only 59% had completed germline testing, with no meaningful difference between academic (58%) and community (60%) settings 1. Somatic testing completion reached only 69% in unresectable and metastatic cases 1. The GENERATE study demonstrated that remote testing models can achieve 90% uptake in highly selected cohorts, but that cohort was 97% non-Hispanic White, 79% college-educated, and predominantly urban—underscoring the deep inequity in real-world access 35.
These gaps have direct therapeutic consequences. BRCA1/2 mutations occur in 4–7% of unselected PDAC patients 23; those with germline BRCA mutations demonstrate significantly superior survival with platinum-based chemotherapy (6.3 vs. 22.9 months; HR 0.34; P <0.01) 23. NCCN guidelines recommend gemcitabine plus cisplatin specifically for BRCA1/2- or PALB2-mutated patients, and olaparib maintenance for those without progression after 4–6 months of platinum-based first-line therapy (median PFS 7.4 vs. 3.8 months, P=0.004) 31. MSI-H tumors—though rare in PDAC—qualify for pembrolizumab, which showed a 62% objective response rate in a small PDAC cohort 33. NTRK fusions are eligible for larotrectinib (75% ORR) or entrectinib (57.4% ORR) 34. Each of these precision opportunities is missed when testing is not performed.
Surgical Candidacy and Referral Management
Surgical resection remains the only potentially curative intervention, yet resection rates remain suboptimal across health systems 10. Improving margin-negative (R0) resection rates depends on timely multidisciplinary staging, neoadjuvant therapy for borderline resectable and locally advanced disease, and centralization to high-volume centers 510. The NEOLAP-AIO-PAK-0113 phase II trial (n=130, Germany) demonstrated surgical conversion rates of 35.9% with gemcitabine/nab-paclitaxel versus 43.9% with sequential FOLFIRINOX in locally advanced disease, with superior histopathological downstaging (ypN0 52% vs. 17%; P=0.02) and ypT1/2 staging (69% vs. 17%; P=0.0003) favoring FOLFIRINOX, though median OS was not significantly different (20.7 vs. 18.5 months) 38. A Japanese phase I study of neoadjuvant gemcitabine/nab-paclitaxel in resectable PDAC achieved an R0 rate of 88.9% in resected patients, with 77.8% initiating adjuvant therapy 39. Despite these advances, fragmented care and inadequate preoperative staging continue to limit surgical outcomes globally 5.
Systemic Therapy Undertreatment and Regimen Selection
In the metastatic setting, 70% of US patients receive standard combination chemotherapy (predominantly FOLFIRINOX or gemcitabine/nab-paclitaxel), with real-world median OS of 8.9 months overall—10.4 months for FOLFIRINOX and 7.9 months for gemcitabine/nab-paclitaxel 17. A large EHR-based study confirmed these findings (FOLFIRINOX 8.6 months vs. 6.1 months) 52. Sequential use of both regimens extended median OS to 11.9–11.5 months 52. Despite trial-established efficacy—PRODIGE trial: FOLFIRINOX 11.1 vs. 6.8 months for gemcitabine (P<0.001) 24, and MPACT trial: gemcitabine/nab-paclitaxel 8.7 vs. 6.6 months (P<0.0001) 27—real-world outcomes lag significantly, reflecting the compounded effects of patient selection, dose modification, and early discontinuation.
FOLFIRINOX eligibility requires ECOG PS 0–1, age up to 75 years, near-normal bilirubin, and normal DPD activity 18. In clinical practice, these criteria exclude many patients, contributing to undertreatment in older, frail, and comorbid populations. Only 30% of patients received second-line treatment after first-line therapy in one real-world analysis 17.
Treatment Adherence and Dose Modifications
A Canadian multicenter cohort study of 71 resected patients found that 31% required early adjuvant chemotherapy discontinuation 3. The survival impact was severe:
| Outcome | Completed Treatment | Early Discontinuation | P-value |
|---|---|---|---|
| Median RFS | 22 months | 9 months | <0.001 |
| Median OS | 33 months | 16 months | <0.001 |
| 5-year OS | 34% | 14% | — |
| HR for recurrence | — | 2.57 (95% CI 1.41–4.68) | 0.002 |
| HR for death | — | 2.55 (95% CI 1.39–4.68) | 0.003 |
Early discontinuation was driven primarily by treatment-related toxicities; patients who discontinued received a mean of 2.9 cycles versus 6.2 cycles in completers 3. Higher post-operative complication rates (73% vs. 35%) and longer hospital stays (22 vs. 13 days) were independently associated with early discontinuation 3. Critically, timing of adjuvant initiation (within vs. beyond 56 days) was not associated with survival differences, suggesting that completion—not speed—is the dominant determinant of benefit 3. An international multicenter cohort of 1,758 resected patients found that only 35.3% of patients achieving pathological complete response after neoadjuvant therapy initiated adjuvant chemotherapy, versus 66.9% in the non-pCR group, reflecting clinical uncertainty in this population 36. Preoperative dose reduction occurred in 14.2% overall 36.
In the FOLFIRINOX era, grade 3–4 toxicity rates include 45.7% neutropenia, 12.7% diarrhea, and 9% sensory neuropathy 24, underscoring the importance of proactive supportive care. Modified FOLFIRINOX (25% dose reductions in bolus 5-FU and irinotecan) preserved OS while reducing toxicity 25.
Multidisciplinary Care and Care Coordination
Multidisciplinary team (MDT) review is foundational to optimal PDAC management 1520, yet the AccessHope analysis found that only 20% of patients had documented palliative or allied health care referrals 1, and 40% were eligible for relevant clinical trials without awareness of opportunities 1. Overall, 85% of cases had recommendations from specialist review that could improve cancer-directed therapy 1. Remarkably, no significant difference in care gaps was found between academic (34% of cases) and community centers (66%), suggesting that the barrier is not simply access to specialist facilities but rather the systematic integration of guideline-concordant care processes 1.
Monitoring and Surveillance
Post-resection surveillance practices remain highly variable. CA19-9 has well-established limitations as a standalone monitoring biomarker. Circulating tumor DNA (ctDNA) shows significant promise as a minimal residual disease (MRD) marker and independent prognostic indicator after surgery, but sensitivity remains limited in low-tumor-burden states, and analytical standardization across platforms is incomplete 7. Optimal surveillance intervals and imaging modalities for high-risk individuals remain subjects of ongoing debate, with limited prospective data guiding recommendations for hereditary cancer syndromes 1951. In clinical practice, adoption of ctDNA MRD assays into routine post-resection pathways has not yet been systematically benchmarked in large registry cohorts.
Nutrition and Metabolic Management
Although the retrieved materials do not provide specific quantitative benchmarks for pancreatic exocrine replacement therapy (PERT) use, cachexia management, or pancreatogenic diabetes control rates, the clinical literature consistently identifies these as underrecognized contributors to treatment intolerance and inferior outcomes. Nutritional depletion and sarcopenia reduce chemotherapy tolerability and compound the risk of early discontinuation—linking this domain directly to the adherence gaps described above 3.
Clinical Trial Access and Enrollment
Only 4.6% of PDAC patients enroll in clinical trials, despite NCCN's unanimous endorsement of trial participation over standard therapy when available 20. In the AccessHope cohort, 40% of patients were eligible for relevant trials but were not enrolled 1. Geographic and demographic barriers are substantial: in 2020, only 17% of US counties had at least one genetic counselor, and only 41% of federal exchange insurance policies provided in-network access to NCI-designated cancer facilities 35. These systemic gaps disproportionately affect rural, lower-income, and minority populations.
Health Equity and Disparities
Racial and ethnic disparities pervade PDAC care across multiple dimensions. Patients of color experience higher rates of pain undertreatment, implicit bias in clinical encounters, and restricted access to opioid-sparing and supportive care services 11. Patient-reported outcome (PRO) monitoring adherence averages only 49.4% across sites in real-world oncology settings, with Black or African American patients and those aged 65 or older showing significantly lower adherence rates (P<0.01 for both) 13. Current risk prediction models may not adequately capture PDAC risk in diverse populations due to underrepresentation in model development cohorts 14. Only 3% of US counties have a genetic counselor, and access concentrates overwhelmingly in urban, affluent areas 35.
Real-World Adherence to Guidelines
The aggregate picture of guideline concordance is sobering. In the most comprehensive real-world US analysis available, only 6% of PDAC patients received completely concordant comprehensive care; 19% had discordant cancer-directed therapy recommendations, and 75% received care with identifiable enhancement opportunities—with coverage not identified as the primary barrier, as 94% had private insurance 1. NCCN guidelines (Version 2.2021) specifically endorse universal germline testing, somatic NGS in advanced disease, FOLFIRINOX or gemcitabine/nab-paclitaxel as first-line preferred regimens, olaparib maintenance for BRCA-mutated metastatic disease, pembrolizumab for MSI-H tumors, and NTRK inhibitors for fusion-positive disease 202122232427313334. The gap between these recommendations and real-world practice represents a significant, actionable target.
Actionable Levers for Quality Improvement
The following seven system-level interventions are supported by the evidence synthesized above and represent the highest-yield opportunities to improve PDAC outcomes:
| Lever | Target Gap | Expected Impact |
|---|---|---|
| 1. Systematic universal germline and somatic testing programs with structured genetic counseling pathways | Testing uptake (59% germline; 69% somatic) | Identifies BRCA/PALB2 patients eligible for platinum therapy and olaparib maintenance; MSI-H for pembrolizumab; NTRK for TRK inhibitors 12131 |
| 2. Standardized MDT review protocols with documented resectability assessment before treatment initiation | Surgical underreferral; R0 optimization | Improves surgical conversion rates (35–44% in locally advanced disease) and margin-negative resection 51038 |
| 3. Proactive toxicity-focused supportive care programs (antiemetics, G-CSF, neuropathy monitoring) to improve adjuvant chemotherapy completion | 31% early discontinuation rate | Completion associated with HR 2.57 reduction in recurrence and HR 2.55 reduction in mortality vs. early discontinuation 3 |
| 4. Early integration of palliative care with standardized PRO collection | 80% lacking documented palliative referral; 49.4% PRO adherence | Improves quality of life and treatment adherence; reduces disparities by race/age 113 |
| 5. Proactive peer-to-peer specialist consultation and telehealth case review models for community and non-NCI centers | Academic-community care gap parity | Targets the 85–94% of cases with identifiable subspecialist enhancement opportunities 1 |
| 6. Centralization of surgical expertise and coordinated neoadjuvant therapy protocols for borderline resectable/locally advanced disease | Suboptimal resection rates; staging gaps | Improved ypN0 and ypT downstaging; potential survival improvement 3810 |
| 7. Equity-focused targeted screening and surveillance programs with community-based genetic counseling and decentralized trial access | Racial/rural disparities; 4.6% trial enrollment | Addresses geographic counselor gaps (17% of US counties covered); increases precision therapy access for underrepresented populations 142035 |
Conclusion
PDAC management in 2026 is characterized by a well-characterized but incompletely addressed set of practice gaps that collectively suppress survival and quality of life across the diagnostic-to-treatment continuum. Diagnostic delays exceeding 25 days double the 1-year mortality risk 2. Germline testing rates of 59% and somatic testing rates of 69% deprive large proportions of patients of precision therapeutic eligibility 1. Early adjuvant chemotherapy discontinuation in 31% of resected patients nearly triples recurrence risk 3. And only 6% of patients receive comprehensively guideline-concordant care 1—a failure that manifests equally in academic and community settings, indicating a systems problem that transcends geography or institutional prestige. The evidence base for targeted intervention is robust; translating it into consistent, equitable, and coordinated care delivery remains the defining challenge of PDAC management in the contemporary era 1216.